Dyax launches newly enhanced product website featuring comprehensive financial assistance program

Jul 20 2010

Dyax Corp. (NASDAQ:DYAX) today announced that it has launched its newly enhanced product website, www.KALBITOR.com, featuring its comprehensive financial assistance program. KALBITOR^® (ecallantide) is approved for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

“We are pleased to offer financial assistance solutions for qualified HAE patients in need”

HAE patients, healthcare professionals and caregivers may contact KALBITOR Access^SM, a one-stop support services program, to learn about comprehensive financial assistance solutions for qualified patients. The KALBITOR Access program also offers reimbursement support services, treatment location coordination and assistance with ordering and shipping KALBITOR. The program team is staffed with dedicated health insurance specialists and nurse case managers to answer questions and to help physicians and their patients ensure that KALBITOR is accessible.

Every patient who enrolls into KALBITOR Access is automatically evaluated for financial assistance with KALBITOR treatment. Based on each patient's eligibility, they may be eligible for:

• KALBITOR free of charge - For qualified uninsured patients
• Co-payment reduction - For qualified insured patients
• Charitable foundation assistance - To subsidize the cost of health insurance premiums and co-pay assistance

"We are pleased to offer financial assistance solutions for qualified HAE patients in need," stated Gustav Christensen, President and Chief Executive Officer of Dyax. "Due to the unpredictable nature of HAE, we believe it is important for patients to enroll into KALBITOR Access to ensure that a treatment plan is in place before the next attack occurs. The enhanced product website is part of our continuous commitment to educate patients who are seeking ways to treat acute HAE attacks. KALBITOR.com provides HAE patients, healthcare professionals and caregivers the opportunity to not only gain a better understanding of HAE but also to help determine if KALBITOR is the right treatment for them."

KALBITOR.com offers comprehensive product information. It also features educational videos on the mechanism of action behind HAE attacks, real patient accounts of life with HAE and information about the risks and benefits of KALBITOR.

"The KALBITOR website is a useful resource for patients interested in learning more about the product or thinking about enrolling into KALBITOR Access," said Greg, who was diagnosed with HAE over 20 years ago. "The KALBITOR Access team has been very helpful in addressing my specific questions and working with my doctor to make the treatment available at a hospital which is around the corner from my house."